Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
Open accessThe DOI matches its Crossref record; 64 of the 67 references it cites were found in a registry or an index.
Abstract
Purpose: To determine the levels of interleukin (IL)-6, vascular endothelial growth factor-A, platelet-derived growth factor, placental growth factor (PLGF), and other cytokines in the aqueous fluid of patients with neovascular age-related macular degeneration who respond poorly to ranibizumab. Patients and methods: This is an observational, prospective study. Thirty-two eyes from 30 patients were included in the study: 11 patients who responded poorly to ranibizumab and were switched to aflibercept (AF group), 8 patients who received ranibizumab and photodynamic therapy (PDT group), and 13 patients who responded to ranibizumab (control group). Aqueous fluid samples were collected for analysis of cytokine levels at baseline and after 1, 2, and 3 months of treatment. The effect of treatment on cytokine levels was compared between the study groups and between different time points using a linear mixed-effect regression model. Results: In the AF group, there was an increase in vascular endothelial growth factor-C, IL-7, and angiopoeitin-2 levels ( P =0.01) and a decrease in intercellular adhesion molecule and IL-17 levels ( P =0.01) between baseline and 3 months. After adjustment for age, sex, race, and type of lesion at baseline, the PLGF level was higher ( P =0.02) and the IL-7 level was lower ( P =0.04) in the ranibizumab non-responder group than in the ranibizumab responder group. Conclusion: Switching from ranibizumab to aflibercept did not reduce intraocular levels of angiogenesis cytokines, but resulted in improvement of central subfield thickness. PLGF levels were higher in poor responders to ranibizumab. The response of lesions to medication might be related to the stage of choroidal neovascularization. Trial registration: www.ClinicalTrial.gov (NCT02218177c). Keywords: neovascular age-related macular degeneration, choroidal neovascularization, anti-VEGF non-responder, poor responder, ranibizumab and AMD
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, no approved therapy for wet AMD targets VEGF-C, a potentially important target and driver of treatment resistance. 21 – 24”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, VEGF-C concentrations are reportedly elevated in the eye following treatment with VEGF-A inhibitors, suggesting that VEGF-A suppression induces compensatory upregulation of VEGF-C. 21 , 23 , 24”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [23]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“and has been shown to promote vessel permeability and vascular leakage. 23”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331 · cited 1×
“Introduction Wet age-related macular degeneration (AMD) is one of the leading causes of blindness in adults and its pathogenesis is characterized by choroidal neovascularization (CNV).(1,2) Ranibizumab (Lucentis; Genentech Inc.”
Global estimates of visual impairment: 2010
Pascolini, D., & Mariotti, S. P. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300539 · Cited by 3,763
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Gene selection and classification of microarray data using random forest
Díaz-Uriarte, R., & Alvarez de Andrés, S. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-3 · Cited by 2,929 · cited 1×
“4, R: A language and environment for statistical computing, 2016; R Foundation for Statistical Computing, Vienna, Austria), propensity score adjustment was performed using the R library twang,(30) and variable selection was performed using the R library varSelRF.(31) A P-value of 0.”
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 3×
“Aflibercept (VEGF Trap; Bayer AG, Leverkusen, Germany; Regeneron, Tarrytown, NY, USA) is a recombinant soluble VEGF receptor protein that has a high affinity for all VEGF isoforms and for PLGF. 10 The VIEW 1 and VIEW 2 studies showed non-inferiority and clinical equivalence of afliber-cept to monthly ranibizumab in th…”
Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice.
Peschon, J. J., Morrissey, P. J., Grabstein, K. H., Ramsdell, F. J., Maraskovsky, E., Gliniak, B. C., Park, L. S., Ziegler, S. F., Williams, D. E., Ware, C. B., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.5.1955 · Cited by 1,555 · cited 1×
“38 IL-7 also has a role in the enhancement of homeostatic proliferation and prolonged survival of naïve T-cells, 39 and inhibition of IL-7 is used in the treatment of patients with lymphopenia.”
McCaffrey, D. F., Ridgeway, G., & Morral, A. R. (2004) · Psychological Methods · doi:10.1037/1082-989x.9.4.403 · Cited by 1,317 · cited 2×
“…that there were three study groups, we could not use a standard approach for propensity score adjustment and instead used the propensity score adjustment method devised by McCaffrey et al. 29 This method uses boosted logistic regression to generate propensity scores across three or more groups.”
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
IL-7 is critical for homeostatic proliferation and survival of naïve T cells
Tan, J. T., Dudl, E., LeRoy, E., Murray, R., Sprent, J., Weinberg, K. I., & Surh, C. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161126098 · Cited by 965 · cited 2×
“38 IL-7 also has a role in the enhancement of homeostatic proliferation and prolonged survival of naïve T-cells, 39 and inhibition of IL-7 is used in the treatment of patients with lymphopenia.”
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849 · cited 3×
“Aflibercept (VEGF Trap; Bayer AG, Leverkusen, Germany; Regeneron, Tarrytown, NY, USA) is a recombinant soluble VEGF receptor protein that has a high affinity for all VEGF isoforms and for PLGF. 10 The VIEW 1 and VIEW 2 studies showed non-inferiority and clinical equivalence of afliber-cept to monthly ranibizumab in th…”
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration
Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.011 · Cited by 822 · cited 1×
“showed non-inferiority and clinical equivalence of aflibercept to monthly ranibizumab in the treatment of wet AMD,(11) with an average of five fewer injections at 96 weeks of treatment.(12) Aflibercept has been reported to be a treatment option for patients who are refractory to ranibizumab and bevacizumab.”
(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Leptin, the Product of Ob Gene, Promotes Angiogenesis
Bouloumié, A., Drexler, H. C. A., Lafontan, M., & Busse, R. (1998) · Circulation Research · doi:10.1161/01.res.83.10.1059 · Cited by 715 · cited 1×
“48,49 Immunohistochemical analysis of CNV membrane tissue revealed leptin staining and absence of leptin staining in normal posterior segment tissue.”
Naldini, L., Vigna, E., Narsimhan, R. P., Gaudino, G., Zarnegar, R., Michalopoulos, G. K., & Comoglio, P. M. (1991) · PubMed · Cited by 698
Bressler, N. M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01237-5 · Cited by 666
Bressler, N. M. (2001) · Cited by 599
Park, H.-Y., Kwon, H. M., Lim, H. J., Hong, B. K., Lee, J. Y., Park, B. E., Jang, Y. S., Cho, S. Y., & Kim, H.-S. (2001) · Experimental & Molecular Medicine · doi:10.1038/emm.2001.17 · Cited by 464 · cited 1×
“48,49 Immunohistochemical analysis of CNV membrane tissue revealed leptin staining and absence of leptin staining in normal posterior segment tissue.”
Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 448 · cited 1×
“…is an affinity-matured antigen-binding fragment (Fab) with high affinity for VEGF-A and neutralizes all human VEGF-A isoforms, except for PLGF. 33,34 Our finding of an increase in the PLGF level in patients who did not respond to ranibizumab mono-therapy is consistent with the evidence of…”
Rosenberg, S. A., Sportès, C., Ahmadzadeh, M., Fry, T. J., Ngo, L. T., Schwarz, S. L., Stetler-Stevenson, M., Morton, K. E., Mavroukakis, S. A., Morre, M., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000210386.55951.c2 · Cited by 443 · cited 1×
“40 IL-7 was found to support both T-cells and B-cells in exacerbating the non-T/ non-B-cell–mediated chronic inflammatory response.”
Grossniklaus, H. E., Ling, J. X., Wallace, T. M., Dithmar, S., Lawson, D., Cohen, C., Elner, V. M., Elner, S. G., & Sternberg, P. (2002) · PubMed · Cited by 434
Schmidt-Erfurth, U. (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.9.1177 · Cited by 364
Rakic, J.-M., Lambert, V., Devy, L., Luttun, A., Carmeliet, P., Claes, C., Nguyen, L., Foidart, J.-M., Noe¨l, A., & Munaut, C. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1092 · Cited by 321 · cited 9×
“50 53 Anti-VEGF monotherapy limits leakage and inhibits vessel growth without complete and sustained resolution of CNV.”
InfluentialSchlötzer-Schrehardt, U., Viestenz, A., Naumann, G. O., Laqua, H., Michels, S., & Schmidt-Erfurth, U. (2002) · Graefe’s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-002-0517-4 · Cited by 278 · cited 2×
“This can be explained by the regression of CNV that occurs in response to PDT. 46,47 Leptin has been found to regulate the tyrosine kinase-dependent intracellular pathway and to stimulate angiogenesis via the leptin receptor (Ob-R).”
Barnes, T. C., Anderson, M. E., & Moots, R. J. (2011) · International Journal of Rheumatology · doi:10.1155/2011/721608 · Cited by 244
Bakall, B., Folk, J. C., Boldt, H. C., Sohn, E. H., Stone, E. M., Russell, S. R., & Mahajan, V. B. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.017 · Cited by 229
Miller, J. W. (1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.9.1161 · Cited by 221 · cited 1×
“17 The VIP study reported that PDT significantly reduced the risk of moderate and severe visual loss in classic CNV and recommended PDT for patients with AMD and subfoveal lesions.”
Kumar, N., Marsiglia, M., Mrejen, S., Fung, A. T.-C., Slakter, J., Sorenson, J., & Freund, K. B. (2013) · Retina · doi:10.1097/iae.0b013e31828e8551 · Cited by 177
Funk, M., Karl, D., Georgopoulos, M., Benesch, T., Sacu, S., Polak, K., Zlabinger, G. J., & Schmidt-Erfurth, U. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.039 · Cited by 175
Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
Binder, S. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301236 · Cited by 169 · cited 7×
“Approximately 1%–10% of patients with CNV secondary to AMD have a poor response to ranibizumab.(23,24) The mechanisms of resistance to intravitreal ranibizumab can be categorized as non-response, development of tolerance, or tachyphylaxis.”
InfluentialAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
Cho, H., Shah, C. P., Weber, M., & Heier, J. S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303344 · Cited by 161 · cited 2×
“13–16 Historically, photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis International AG, Basel, Switzerland) was the standard treatment for neovascular AMD before the approval of anti-VEGF.”
Izumi‐Nagai, K., Nagai, N., Ozawa, Y., Mihara, M., Ohsugi, Y., Kurihara, T., Koto, T., Satofuka, S., Inoue, M., Tsubota, K., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061018 · Cited by 157
Targeted Disruption of the CD18 or ICAM-1 Gene Inhibits Choroidal Neovascularization
Sakurai, E., Taguchi, H., Anand, A., Ambati, B. K., Gragoudas, E. S., Miller, J. W., Adamis, A. P., & Ambati, J. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1246 · Cited by 145 · cited 8×
“50 53 Anti-VEGF monotherapy limits leakage and inhibits vessel growth without complete and sustained resolution of CNV.”
InfluentialTachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab
Eghøj, M. S., & Sørensen, T. L. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2011.203893 · Cited by 143 · cited 1×
“23,24 The mechanisms of resistance to intravitreal ranibizumab can be categorized as non-response, development of tolerance, or tachyphylaxis.”
Lashkari, K., Hirose, T., Yazdany, J., McMeel, J. W., Kazlauskas, A., & Rahimi, N. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65004-3 · Cited by 143 · cited 1×
“Hera et al reported that in 18 CNV membranes secondary from AMD showed low expression of VEGF-A and that expression of this cytokine correlated with the activity of CNV. HGF has been reported to be increased in retinopathy of prematurity 56 and retinal detachment, 57 and is induced by FGF-2.”
Higgins, G. T., Wang, J. H., Dockery, P., Cleary, P. E., & Redmond, H. P. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0742 · Cited by 121 · cited 1×
“45 Grossniklaus et al studied surgically excised subfoveal CNV specimens from an eye bank and found that VEGF tissue factor and MCP-1 expression levels were higher in specimens with “inflammatory active” CNV than in those with fibrotic “inflammatory inactive” CNV.”
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
VANDER, J. F. (2007) · Yearbook of Ophthalmology · doi:10.1016/s0084-392x(08)70110-2 · Cited by 114
Roh, M., Kim, H. S., Song, J. H., Lim, J., Koh, H. J., & Kwon, O. W. (2009) · Retina · doi:10.1097/iae.0b013e318195cb15 · Cited by 110
Hepatocyte growth factor/Scatter factor in the eye
Grierson, I., Heathcote, L., Hiscott, P. S., Hogg, P., Briggs, M., & Hagan, S. (2000) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00015-x · Cited by 107
Wykoff, C. C., Brown, D. M., Maldonado, M. E., & Croft, D. E. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304736 · Cited by 96
REPRODUCIBILITY OF REFRACTION AND VISUAL ACUITY MEASUREMENT UNDER A STANDARD PROTOCOL
Blackhurst, D. W., & Maguire, M. G. (1989) · Retina · doi:10.1097/00006982-198909030-00001 · Cited by 93
Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration
Muether, P. S., Hoerster, R., Hermann, M. M., Kirchhof, B., & Fauser, S. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2038-0 · Cited by 88 · cited 1×
“36,37 Funk et al studied the change in aqueous VEGF of ranibizumab in AMD from baseline to 12 months follow-up; the level of VEGF was markedly reduced after the first treatment injection and was below the level of detection after repeated treatment.”
Fitting concentration and load rating curves with generalized linear models
Cox, N. J., Warburton, J., Armstrong, A., & Holliday, V. J. (2007) · Earth Surface Processes and Landforms · doi:10.1002/esp.1523 · Cited by 77 · cited 1×
“…an approach to estimate the values censored by the LODs that uses gamma distributions, the parameters (shape and scale) of which were estimated based on data at hand 27 (values above the lower LOD), and then using Monte Carlo simulation 28 to sample values that were lower than the lower LOD.”
(2000) · Time to knit · doi:10.1016/j.yoph.2014.02.025 · Cited by 76
Muether, P. S., Hermann, M. M., Viebahn, U., Kirchhof, B., & Fauser, S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.041 · Cited by 74
IL-7 Deficiency Prevents Development of a Non-T Cell Non-B Cell-Mediated Colitis
von Freeden-Jeffry, U., Davidson, N. J., Wiler, R., Fort, M. M., Burdach, S. E. G., & Murray, R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5673 · Cited by 64 · cited 1×
“to support both T-cells and B-cells in exacerbating the non-T/ non-B-cell–mediated chronic inflammatory response.(41)”
Hepatocyte Growth Factor and its Role in the Pathogenesis of Retinal Detachment
Jin, M., Chen, Y., He, S., Ryan, S. J., & Hinton, D. R. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0355 · Cited by 53 · cited 1×
“Hera et al reported that in 18 CNV membranes secondary from AMD showed low expression of VEGF-A and that expression of this cytokine correlated with the activity of CNV. HGF has been reported to be increased in retinopathy of prematurity 56 and retinal detachment, 57 and is induced by FGF-2.”
Hermann, M. M., van Asten, F., Muether, P. S., Smailhodzic, D., Lichtner, P., Hoyng, C. B., Kirchhof, B., Grefkes, C., den Hollander, A. I., & Fauser, S. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.047 · Cited by 51 · cited 1×
“26 The objective of this study was to determine the levels of IL-6, VEGF, PLGF, and other cytokines in the aqueous humor of patients with AMD who are resistant or poor responders to treatment with ranibizumab.”
Ranibizumab for Neovascular Age-Related Macular Degeneration
VANDER, J. F. (2007) · Yearbook of Ophthalmology · doi:10.1016/s0084-392x(08)70109-6 · Cited by 49
Schmidt-Erfurth, U. M., Wolf, S., & for the PROTECT Study Group (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.135277 · Cited by 40
Fauser, S., Viebahn, U., & Muether, P. S. (2015) · Acta Ophthalmologica · doi:10.1111/aos.12770 · Cited by 37 · cited 1×
“44 IL-8 and MCP-1 have been found to promote angiogenesis via accumulation of macrophages that release angiogenic promoters and degrade Bruch’s membrane.”
Spielberg, L., & Leys, A. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1256-6 · Cited by 31
Massougnes, S. D., Dirani, A., Ambresin, A., Decugis, D., Marchionno, L., & Mantel, I. (2015) · Retina · doi:10.1097/iae.0000000000000813 · Cited by 29 · cited 1×
“despite successful anatomic treatment after switching from ranibizumab to aflibercept in refractory cases.(36,37) Funk et al”
McCaffrey, D. F., Ridgeway, G. K., & Morral, A. R. (2004) · American Psychological Association eBooks · doi:10.7249/rp1164 · Cited by 29
Ahn, J. K., & Moon, H. J. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.06.012 · Cited by 28
Dennig, D., de Lacerda, J. F., Yan, Y., Gasparetto, C., & O’Reilly, R. J. (1994) · Cellular Immunology · doi:10.1006/cimm.1994.1186 · Cited by 25 · cited 1×
“43 Fauser et al studied cytokine levels in the aqueous humor of eyes with naïve AMD that underwent cataract surgery or treat-ment with ranibizumab and reported elevation of MCP-1 and VCAM in the patients with neovascular AMD when compared with controls.”
Miller, J. W., Schmidt-Erfurth, U., Sickenberg, M., Pournaras, C. J., Laqua, H., Barbazetto, I., Zografos, L., Piguet, B., Donati, G., Lane, A. M., et al. (1999) · Infoscience (Ecole Polytechnique Fédérale de Lausanne) · Cited by 17
The role of leptin in choroidal neovascularization
Cui, J. Z., Hornan, D., Potter, M. J., Greve, M. D. J., Hinz, B. J., Samad, A., & Matsubara, J. A. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01105-9 · Cited by 12 · cited 1×
“50 53 Anti-VEGF monotherapy limits leakage and inhibits vessel growth without complete and sustained resolution of CNV.”
Wolf-Schnurrbusch, U. E. K., Brinkmann, C. K., Berger, L., & Wolf, S. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01747.x · Cited by 8 · cited 1×
“19–21 This combination treatment has also been used as a rescue therapy in patients with AMD who fail anti-VEGF monotherapy.”
Lanzetta, P. (2007) · Investigative Ophthalmology & Visual Science · Cited by 2
Larsen, B. P., Davis, M. J., Mudvari, S. S., MacCumber, M. W., & Merrill, P. T. (2009) · Investigative Ophthalmology & Visual Science · Cited by 2
Rescue Therapy With Combined Anti-vegf And Pdt For Refractory AMD
Tozer, K. R., Chong, L. P., & Sadda, S. R. (2011) · Investigative Ophthalmology & Visual Science · Cited by 1
Research works printed but not linked: 2
- [28]Robert CP Monte Carlo Methods Wiley Online Library 2004
- [53]Izumi-Nagai K Nagai N Ozawa Y Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization Am J Pathol 2007 170 6 2149 2158 17525280 PMC1899441
Cited by
VEGFR1 signaling in retinal angiogenesis and microinflammation
Uemura, A., Fruttiger, M., D'Amore, P. A., De Falco, S., Joussen, A. M., Sennlaub, F., Brunck, L. R., Johnson, K. T., Lambrou, G. N., Rittenhouse, K. D., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100954 · Cited by 354
“…growth factors and pro-inflammatory mediators after anti-VEGF treatment in subpopulations of patients categorized as low- to non-responders (Pongsachareonnont et al., 2018), suggesting that there is complexity in the underlying mechanisms of inflammation, and in the identification and role…”
BackgroundTian, Y., Zhang, F., Qiu, Y., Wang, S., Li, F., Zhao, J., Pan, C., Tao, Y. K., Yu, D., & Wei, W. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00764-3 · Cited by 158
The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases
Bergen, T. V., Etienne, I., Cunningham, F., Moons, L., Schlingemann, R. O., Feyen, J. H. M., & Stitt, A. W. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.10.006 · Cited by 120
“Moreover, a very recent paper reported that aqueous PlGF levels were significantly higher in nvAMD patients who responded poorly to ranibizumab than in those who responded to the therapy (Pongsachareonnont et al., 2018).”
Balser, C., Wolf, A., Herb, M., & Langmann, T. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1419-2 · Cited by 62
“Thus, increased PGF has been identified in ocular fluids and tissue from patients with diabetic retinopathy [11, 12]), glaucoma [13], and neovascular AMD [14, 15].”
BackgroundInfluentialLitwińska, Z., Sobuś, A., Łuczkowska, K., Grabowicz, A., Mozolewska‐Piotrowska, K., Safranow, K., Kawa, M. P., Machaliński, B., & Machalińska, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00286 · Cited by 56
Metadata
- Authors
- Pongsachareonnont, P., Ying Kit Mak, M., Hurst, C., & Lam, W.-C.
- Affiliations
- Thai Red Cross Society (TH)
- Chulalongkorn University (TH)
- University of Toronto (CA)
- Corresponding author
- Lam, Wai-Ching
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2018-09
- Volume
- Volume 12
- Pages
- 1877-1885
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC6165786
- OpenAlex
- W2894158365
- Cited by
- 34
- References
- 67
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 2 · 2022: 5 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 1
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, anti-VEGF therapy, aflibercept, aqueous humor, IL-7, placental growth factor, vascular endothelial growth factor, angiogenesis, photodynamic therapy, treatment response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
